Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-26T12:14:32.394Z Has data issue: false hasContentIssue false
  • English
  • Français

Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial☆

Published online by Cambridge University Press:  06 December 2011

E. Johnsen ,
H.A. Jørgensen ,
R.A. Kroken  and
E.-M. Løberg
E. Johnsen*
Affiliation:
Division of Psychiatry, Haukeland University Hospital, Sandviken, Department of Clinical Medicine, Psychiatry, University of Bergen, Norway Sandviksleitet 1, 5035Bergen, Norway
H.A. Jørgensen
Affiliation:
Department of Clinical Medicine, Psychiatry, University of Bergen, Sandviksleitet 1, 5035Bergen, Norway
R.A. Kroken
Affiliation:
Division of Psychiatry, Haukeland University Hospital, Sandviken, Sandviksleitet 1, 5035Bergen, Norway
E.-M. Løberg
Affiliation:
Division of Psychiatry, Haukeland University Hospital, Sandviken, Norway, University of Bergen, Inst. Biological and Medical Psychology, Sandviksleitet 1, 5035Bergen, Norway
*
⁎Corresponding author. E-mail address:[email protected] (E. Johnsen).
Get access

Abstract

Purpose

Cognitive effects of second generation antipsychotics (SGAs) are indicated in efficacy studies but the generalizability of the results may be limited by rigid designs and selected samples. The aim of this naturalistic, industry-independent study is to investigate whether differential neurocognitive effectiveness can be found among olanzapine, quetiapine, risperidone, and ziprasidone in a clinically relevant sample with psychosis.

Subjects and methods

Adult patients acutely admitted to an emergency ward for psychosis were randomized to risperidone, olanzapine, quetiapine or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using the Positive and Negative Syndrome Scale and a repeatable neurocognitive test battery.

Results

A total of 226 patients were included and 171 patients underwent neurocognitive assessments. The sample had a global cognitive performance score at baseline about one standard deviation below that of the general population. The ziprasidone group had the fastest increase in global functioning which was significantly superior to that of the olanzapine group for the entire follow-up period. Before 90 days, the quetiapine group had the fastest increase which was statistically superior to the olanzapine group.

Discussion

Ziprasidone and quetiapine demonstrated superiority to olanzapine in increasing global neurocognitive performance in this naturalistic sample.

Keywords

AntipsychoticsCognitive symptomsRandomized controlled trialPsychoses
Type
Original article
Information
European Psychiatry , Volume 28 , Issue 3 , March 2013 , pp. 174 - 184
Copyright
Copyright © European Psychiatric Association 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

☆

Trial Registration: ClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/:NCT00932529.

References

Bilder, R.M.Goldman, R.S.Volavka, J.Czobor, P.Hoptman, M.Sheitman, B., et al.Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018–1028.CrossRefGoogle ScholarPubMed
Campbell, N.Boustani, M.Limbil, T.Ott, C.Fox, C.Maidment, I., et al.The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009;4:2252–2333.Google ScholarPubMed
Cuesta, M.J.de Jalón, E.G.Campos, M.S.Peralta, V.Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 2009;194:439–445.CrossRefGoogle ScholarPubMed
Davidson, M.Galderisi, S.Weiser, M.Werbeloff, N.Fleischhacker, W.W.Keefe, R.S., et al., Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009;166:675–682.CrossRefGoogle Scholar
Davis, J.M.Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974;11:65–69.CrossRefGoogle ScholarPubMed
Dominguez, M.de, G.Viechtbauer, W.Simons, C.J.van Os, J.Krabbendam, L.Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull 2009;135:157–171.CrossRefGoogle Scholar
Drake, R.E.Rosenberg, S.D.Mueser, K.T.Assessing substance use disorder in persons with severe mental illness. New Dir Health Serv 1996;70:3–17.CrossRefGoogle Scholar
Green, M.F.What are the functional consequences of neurocognitive deficits in schizophrenia. Am J Psychiatry 1996;153:321–330.Google Scholar
Gray, J.A.Roth, B.L.Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007;33:1100–1119.CrossRefGoogle Scholar
Harvey, P.D.Patterson, T.L.Potter, L.S.Zhong, K.Brecher, M.Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 2006;163:1918–1925.CrossRefGoogle ScholarPubMed
Harvey, P.D.Sacchetti, E.Galluzzo, A.Romeo, F.Gorini, B.Bilder, R.M., et al., A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophr Res 2008;105:138–143.CrossRefGoogle ScholarPubMed
Harvey, P.D.Bowie, C.R.Loebel, A.Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci 2006;18:54–63.CrossRefGoogle ScholarPubMed
Heaton, R.K.Gladsjo, J.A.Palmer, B.W.Kuck, J.Marcotte, T.D.Jeste, D.V.Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001;58:24–32.CrossRefGoogle Scholar
Heaton, R.K.Grant, I.Matthews, C.G.Comprehensive norms for an expanded Halstead-Reitan battery. Demographic corrections, research findings, and clinical applications. Psychological assessment resources 1991, Odessa, Florida, USA.Google Scholar
Hedden, S.L.Woolson, R.F.Carter, R.E.Palesch, Y.Ypadhyaya, H.P.Malcolm, R.J.The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse trials. J Subst Abuse Treat 2009;37:54–63.CrossRefGoogle Scholar
Higgins, J.P.T.Green, S., editors. Cochrane handbook for systematic reviews of interventions 4.2.6. http://www.cochrane.org/resources/handbook/hbook.htm; 2006 [accessed 23rd April 2009].Google Scholar
Hill, S.K.Reilly, J.L.Harris, M.S.H.Rosen, C.Marvin, R.W.Deleon, O., et al., A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr Res 2009;113(a):167–175.CrossRefGoogle Scholar
Johnsen, E.Kroken, R.A.Wentzel-Larsen, T.Jørgensen, H.A.Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 2010;10:26.CrossRefGoogle ScholarPubMed
Kahn, R.Fleischhacker, W.W.Boter, H.Davidson, M.Vergouwe, Y.Keet, I.P.M., et al., Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008;371:1085–1097.CrossRefGoogle Scholar
Kay, S.R.Fiszbein, A.Opler, L.A.The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.CrossRefGoogle Scholar
Keefe, R.S.E.Bilder, R.M.Davis, S.M.Harvey, P.D.Palmer, B.W.Gold, J.M., et al., Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64:633–647.CrossRefGoogle ScholarPubMed
Keefe, R.S.E.Fox, K.H.Harvey, P.D.Cucchiaro, J.Siu, C.Loebel, A.Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 2011;125:161–168.CrossRefGoogle Scholar
Keefe, R.S.E.Sweeney, J.A.Gu, H.Hamer, R.M.Perkins, D.O.McEvoy, J.P., et al., Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1061–1071.CrossRefGoogle ScholarPubMed
Leucht, S.Heres, S.Hamann, J.Kane, J.M.Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008;34:275–285.CrossRefGoogle ScholarPubMed
Løberg, E.M.Langeland, M.Jørgensen, H.A.Reliability and validity of a Norwegian translation of the repeatable battery for the assessment of neuropsychological status in patients with psychosis. 10 year anniversary of the Norwegian neuropsychological association 2006 [Abstract].Google Scholar
March, J.S.Silva, S.G.Compton, S.Shapiro, M.Califf, R.Krishnan, R.The case for practical clinical trials in psychiatry. Am J Psychiatry 2005;162:836–846.CrossRefGoogle ScholarPubMed
Marder, S.R.Lessons from MATRICS. Schizophr Bull 2011;37:233–234.CrossRefGoogle ScholarPubMed
Palmer, B.W.Dawes, S.E.Heaton, R.K.What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol Rev 2009;19:365–384.CrossRefGoogle ScholarPubMed
Pinheiro, C.Bates, D.M.Mixed effects models in S and S-plus. New York: Springer; 2000.CrossRefGoogle Scholar
R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria 2008. ISBN 3-900051-07-0. http://www.r-project.org/ [accessed November 02, 2008].Google Scholar
Randolph, C.Tierney, M.C.Mohr, E.Chase, T.N.The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310–319.CrossRefGoogle ScholarPubMed
Riedel, M.Schennach-Wolff, R.Musil, R.Dehning, S.Cerovecki, A.Opgen-Rhein, M., et al., Spellmann. Neurocognition and its influencing factors in the treatment of schizophrenia – effects of aripiprazole, olanzapine, quetiapine, and risperidone. Hum Psychopharmacol Clin Exp 2010;25:116–125.CrossRefGoogle ScholarPubMed
Riedel, M.Müller, N.Spellmann, I.Engel, R.R.Musil, R.Valdevit, R., et al., Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007;257:402–412.CrossRefGoogle ScholarPubMed
Riedel, M.Spellmann, I.Strassnig, M.Douhet, A.Dehning, S.Opgen-Rhein, M., et al., Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2007;257:360–370.CrossRefGoogle ScholarPubMed
Robles, O.Zabala, A.Bombín, I.Parellada, M.Moreno, D.Ruiz-Sancho, A., et al., Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. Schizophr Bull 2011;37:405–415.CrossRefGoogle ScholarPubMed
Ronning, M.The WHO collaborating centre for drug statistics methodology. Established 1982, http://www.whocc.no/atcddd/ [accessed November 02, 2008].Google Scholar
Smith, M.J.Barch, D.M.Csernansky, J.G.Bridging the gap between schizophrenia and psychotic mood disorders: relating neurocognitive deficits to psychopathology. Schizophr Res 2009;107:69–75.CrossRefGoogle ScholarPubMed
Tandon, R.Belmaker, R.H.Gattaz, W.F.Lopez-Ibor, J.J.Okasha, A.Singh, B., et al., Section of pharmacopsychiatry. World psychiatric association. World psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20–38.CrossRefGoogle ScholarPubMed
Van Veelen, N.M.J.Grootens, K.P.Peuskens, J.Sabbe, B.G.Salden, M.E.Verkes, R.J., et al., Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophr Res 2010;120:191–198.CrossRefGoogle ScholarPubMed
Voruganti, L.P.Awad, A.G.Parker, G.Forrest, C.Usmani, Y.Fernando, M.L., et al., Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 2007;96:146–155.CrossRefGoogle ScholarPubMed
Wilk, C.M.Gold, J.M.Bartko, J.J.Dickerson, F.Fenton, W.S.Knable, M., et al., Test-retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia. Am J Psychiatry 2002;159:838–844.CrossRefGoogle Scholar
World Health Organization. International statistical classification of diseases and related health problems. 10th revision, version for 2007. World Health Organization/German Institute of medical documentation and information; 1994/2006; http://www.who.int/classifications/apps/icd/icd10online/ [accessed March 13, 2011].Google Scholar
Woodward, N.D.Purdon, S.E.Meltzer, H.Y.Zald, D.H.A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005;8:457–472.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.